Eupraxia Pharmaceuticals (TSX:EPRX) FCF Yield %: -7.50 (As of Jun. 29, 2026)


TSX:EPRX Eupraxia Pharmaceuticals Inc TSX:EPRX
37 GF Score
Price C$9.35
! 1 Warning Sign
View Full Analysis

What is Eupraxia Pharmaceuticals FCF Yield %?

Eupraxia Pharmaceuticals TSX:EPRX +2.85% 37 FCF Yield % is -7.50 as of Jun. 29, 2026. GuruFocus rates TSX:EPRX with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 1,415 Biotechnology companies, Eupraxia Pharmaceuticals ranks better than 54.56% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Eupraxia Pharmaceuticals's Trailing 12-Month Free Cash Flow is C$-45.97 Mil, and Market Cap is C$612.77 Mil. Therefore, Eupraxia Pharmaceuticals's FCF Yield % for today is -7.50%.

The historical rank and industry rank for Eupraxia Pharmaceuticals's FCF Yield % or its related term are showing as below:

TSX:EPRX' s FCF Yield % Range Over the Past 10 Years
Min: -7.5   Med: 0   Max: 0
Current: -7.5

TSX:EPRX's FCF Yield % is ranked better than
54.56% of 1415 companies
in the Biotechnology industry
Industry Median: -9.62 vs TSX:EPRX: -7.50

Eupraxia Pharmaceuticals's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

Eupraxia Pharmaceuticals FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Eupraxia Pharmaceuticals FCF Yield % Related Terms

Eupraxia Pharmaceuticals FCF Yield % Historical Data

* Premium members only.

The historical data trend for Eupraxia Pharmaceuticals's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eupraxia Pharmaceuticals FCF Yield % Chart

Eupraxia Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial Premium Member Only -43.36 -25.22 -19.07 -26.68 -7.50

Eupraxia Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.04 -16.45 -6.09 -10.21 -9.26

TSX:EPRX vs VRTX, REGN, ALNY: FCF Yield % Comparison

For the Biotechnology subindustry, Eupraxia Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eupraxia Pharmaceuticals FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eupraxia Pharmaceuticals's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Eupraxia Pharmaceuticals's FCF Yield % falls into.


TSX:EPRX
37GF Score
Eupraxia Pharmaceuticals Inc TSX:EPRX
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eupraxia Pharmaceuticals FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Eupraxia Pharmaceuticals's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-40.2 / 536.01048
=-7.50%

Eupraxia Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-14.371 * 4 / 620.56236
=-9.26%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -7.50 mean?
Eupraxia Pharmaceuticals (TSX:EPRX) has a FCF Yield % of -7.50 as of Jun. 29, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Eupraxia Pharmaceuticals and its competitors. According to the industry distribution chart, Eupraxia Pharmaceuticals ranks #643 out of 1415 companies in the Biotechnology industry, placing it in the top 45.4%.
Is Eupraxia Pharmaceuticals' FCF Yield % too high?
Eupraxia Pharmaceuticals' current FCF Yield % is -7.50. Based on the distribution chart, Eupraxia Pharmaceuticals ranks #643 out of 1415 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Eupraxia Pharmaceuticals has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Eupraxia Pharmaceuticals' FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Eupraxia Pharmaceuticals ranks #643 out of 1415 companies for FCF Yield %. This puts Eupraxia Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Eupraxia Pharmaceuticals and its competitors. Eupraxia Pharmaceuticals's current FCF Yield % is -7.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eupraxia Pharmaceuticals stock overvalued right now?
Eupraxia Pharmaceuticals (TSX:EPRX) has a current FCF Yield % of -7.50. The current FCF Yield % is -7.50. Eupraxia Pharmaceuticals' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Eupraxia Pharmaceuticals (TSX:EPRX), the current FCF Yield % is -7.50 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eupraxia Pharmaceuticals Business Description

Other Exchanges EPRX:USAX43:Germany
Address 201 2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
37GF Score

Get the complete analysis for TSX:EPRX

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$9.35
Price